Search results
Showing 946 to 960 of 1305 results for long term conditions
This quality standard covers the clinical assessment and management of depression in adults aged 18 and over. It describes high-quality care in priority areas for improvement.
View quality statements for QS8Show all sections
Sections for QS8
- Quality statements
- Quality statement 1: Assessment
- Quality statement 2: Discussing treatment options
- Quality statement 3: Preventing relapse
- Quality statement 4: Stopping antidepressants
- Quality statement 5: Access to services for adults from minority ethnic backgrounds
- Update information
- About this quality standard
This guideline covers keeping adults in care homes safe from abuse and neglect. It includes potential indicators of abuse and neglect by individuals or organisations, and covers the safeguarding process from when a concern is first identified through to section 42 safeguarding enquiries. There are recommendations on policy, training, and care home culture, to improve care home staff awareness of safeguarding and ensure people can report concerns when needed.
Arsenic trioxide for treating acute promyelocytic leukaemia (TA526)
Evidence-based recommendations on arsenic trioxide (Trisenox) for treating acute promyelocytic leukaemia in adults.
This quality standard covers the provision of support for adults aged 18 or over who provide unpaid care for 1 or more people aged 16 or over with health and social care needs. It describes high-quality care in priority areas for improvement.
Evidence-based recommendations on cemiplimab (Libtayo) with platinum-based chemotherapy for untreated advanced non-small-cell lung cancer in adults.
Cannabidiol with clobazam for treating seizures associated with Dravet syndrome (TA614)
Evidence-based recommendations on cannabidiol (Epidyolex) with clobazam for seizures associated with Dravet syndrome in people aged 2 years and older.
measures (for example for depression and anxiety). People with a long-term physical health condition are more...
Evidence-based recommendations on the bisphosphonates alendronic acid, ibandronic acid, risedronate sodium and zoledronic acid for treating osteoporosis.
Machine perfusion systems and cold static storage of kidneys from deceased donors (TA165)
Evidence-based recommendations on machine perfusion systems and cold static storage of kidneys from deceased donors.
This quality standard covers the management of acute upper gastrointestinal bleeding in adults and young people (aged 16 and over). It describes high-quality care in priority areas for improvement.
View quality statements for QS38Show all sections
Sections for QS38
- Quality statements
- Quality statement 1: Risk assessment
- Quality statement 2: Immediate endoscopy for people who are haemodynamically unstable
- Quality statement 3: Endoscopy within 24 hours for people who are haemodynamically stable
- Quality statement 4: Endoscopic treatment for non-variceal bleeding
- Quality statement 5: Treatment of non-variceal bleeding after first or failed endoscopic treatment
- Quality statement 6: Prophylactic antibiotic therapy for variceal bleeding
- Quality statement 7: Band ligation for oesophageal variceal bleeding
Pulmonary artery pressure technologies for remote monitoring of chronic heart failure (HTG769)
Evidence-based recommendation on the routine use of pulmonary artery pressure technologies for remote monitoring of chronic heart failure.
Evidence-based recommendations on dabigatran etexilate (Pradaxa) for preventing stroke and systemic embolism in adults with non-valvular atrial fibrillation.
This guideline covers diagnosing and managing non-small-cell and small-cell lung cancer. It aims to improve outcomes for patients by ensuring that the most effective tests and treatments are used, and that people have access to suitable palliative care and follow-up.
Evidence-based recommendations on encorafenib (Braftovi) plus cetuximab (Erbitux) for treating BRAF V600E mutation-positive metastatic colorectal cancer in adults who have had previous systemic treatment.
Evidence-based recommendations on ceftazidime with avibactam for treating severe drug-resistant gram-negative bacterial infections.
View recommendations for AMR1Show all sections